Verve Therapeutics (NASDAQ:VERV) is a clinical-stage biotechnology company focused on developing in vivo gene editing therapies to address cardiovascular disease. Founded in 2018, the company applies its proprietary base-editing platform to introduce targeted, permanent changes to genes involved in lipid metabolism. By harnessing CRISPR-derived technology, Verve aims to reduce lifelong risk of heart attack and stroke through a one-time therapy designed to lower levels of atherogenic lipoproteins.
The company’s lead program, VERVE-101, targets the PCSK9 gene to achieve sustained reductions in low-density lipoprotein cholesterol (LDL-C). Preclinical studies have demonstrated durable editing of hepatocytes and dose-dependent decreases in circulating LDL-C, setting the stage for initial human trials. Verve’s pipeline also includes discovery-stage programs aimed at ANGPTL3 and other targets implicated in dyslipidemia and cardiovascular risk, underscoring its broader commitment to gene editing as a transformative approach for chronic diseases.
Headquartered in Cambridge, Massachusetts, Verve Therapeutics operates research facilities in the heart of the U.S. biotech corridor. Its scientific team draws on expertise in molecular biology, genomics and cardiovascular medicine, while collaborations with academic institutions and clinical partners support both preclinical development and the design of upcoming clinical studies. The company’s strategic focus remains on rigorous safety evaluation and regulatory engagement to advance its therapies toward potential regulatory approval.
Leadership at Verve includes co-founder and CEO Sekar Kathiresan, a cardiologist and geneticist with a track record in cardiovascular genetics research. The management team comprises seasoned professionals in drug development, clinical operations and regulatory affairs, supported by a board of directors featuring experts in biotechnology investment and translational science. Together, they aim to translate cutting-edge gene editing innovations into durable therapies for patients at risk of cardiovascular events worldwide.
